<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690261</url>
  </required_header>
  <id_info>
    <org_study_id>200709004R</org_study_id>
    <nct_id>NCT00690261</nct_id>
  </id_info>
  <brief_title>The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction</brief_title>
  <official_title>The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the correlation between M1/M2 phenotype of tumor&#xD;
      associated macrophage (TAM) in lung cancer patients and clinical outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory response in the tumor micro-environment may facilitate the metastatic process&#xD;
      (1). Macrophages are pivotal members of the inflammatory cells and the innate immune system&#xD;
      within the tumor stroma. Tumor-associated macrophages can release growth factors, cytokines&#xD;
      and inflammatory mediators that may facilitate cancer cell invasion, migration, angiogenesis,&#xD;
      tumor progression or metastasis (1-5). A lot of studies showed TAM encounter factors that&#xD;
      most frequently polarize them toward M2 type macrophage (1,4-5). It is interesting that in&#xD;
      vitro studies macrophages have the potential to kill tumor by appropriate stimulation but&#xD;
      these macrophage belonged to M1 and were not present in most tumor tissue (6). Some drugs&#xD;
      target to suppress TAM have the promising results in animal models (7-9). Switching the TAM&#xD;
      phenotype from M2 to M1 may promote anti-tumor activity (10). In this study we will correlate&#xD;
      TAM M1/M2 ratio and patients' prognosis, the gene expression pattern of TAM.&#xD;
&#xD;
      References&#xD;
&#xD;
        1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-867.&#xD;
&#xD;
        2. Crowther M, Brown NJ, Bishop ET, Lewis CE. Microenvironmental influence on macrophage&#xD;
           regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol&#xD;
           2001;70(4):478-490.&#xD;
&#xD;
        3. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating Factor 1 Promotes&#xD;
           Progression of Mammary Tumors to Malignancy. J. Exp. Med. 2001;193(6):727-740.&#xD;
&#xD;
        4. Mantovani A. Cancer Inflammation by remote control. Nature 2005;435(7043):752-753.&#xD;
&#xD;
        5. Pollard JW. Tumor-educated macrophages promote tumour progression and metastasis. Nature&#xD;
           Reviews Cancer 2004;4(1):71-78.&#xD;
&#xD;
        6. Sica A, Schippa T, Mantovani A, Allavena P. Tumor-associated macrophage are distinct M2&#xD;
           polarized population promoting tumor progression: potential targets of anti-tumor&#xD;
           therapy. Eur J of Cancer 2006;42:717-27&#xD;
&#xD;
        7. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma&#xD;
           after treatment with platinum and taxanes fails. J Clin Oncol 2005;23:1867-74.&#xD;
&#xD;
        8. Wahl L, Kleinman HK. Tumor-associated macrophages as targets for cancer therapy. J Natl&#xD;
           Cancer Inst 1998;90:1583-4.&#xD;
&#xD;
        9. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing&#xD;
           macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest&#xD;
           2004;114:623-33.&#xD;
&#xD;
       10. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo&#xD;
           elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.&#xD;
           Cancer Res 2005;65:3437-46.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>outcome (treatment response and mortality)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical presentation</measure>
    <time_frame>at enrollement</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tumor</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>lung cancer</arm_group_label>
    <description>patients diagnosed of lung cancer with malignant pleural effusions</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Pleural effusions and lung cancer tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients diagnosed of lung cancer with malignant pleural effusions&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  lung cancer with malignant pleural effusions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chao-Chi Ho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine and Emergency Medicine, National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chao-Chi Ho, Ph.D.</last_name>
    <phone>886-2-2356-2905</phone>
    <email>ccho1203@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ang Yuan, Ph.D.</last_name>
    <email>navyyuan@ntu.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao-Chi Ho</last_name>
      <phone>886-2-2356-2905</phone>
      <email>ccho1203@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>June 1, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>June 3, 2008</last_update_submitted>
  <last_update_submitted_qc>June 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Chao-Chi Ho</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>tumor associated macrophage</keyword>
  <keyword>lung cancer</keyword>
  <keyword>outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

